Multiple Myeloma Research Foundation

K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Monday, December 4, 2023
Multiple myeloma, Therapy, ASH, Multiple Myeloma Research Foundation, Poster, Research, Exposition, Society, Relapse, Pharmaceutical industry, Patient, K36

CAMBRIDGE, Mass., Dec. 4, 2023 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14) multiple myeloma, today announced that its abstract evaluating KTX-1001 in relapsed and refractory multiple myeloma has been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 9-12, 2023, in San Diego, California, and online. Dr. Jesús G. Berdeja, the Director of Multiple Myeloma Research at Tennessee Oncology, will deliver the presentation as part of the Trials in Progress session.

Key Points: 
  • Dr. Jesús G. Berdeja, the Director of Multiple Myeloma Research at Tennessee Oncology, will deliver the presentation as part of the Trials in Progress session.
  • "I am delighted to be presenting the trial progress of KTX-1001 in high-risk subsets like translocation t(4;14)," stated Dr. Berdeja.
  • "There still remains an unmet need for new personalized oral therapies to treat multiple myeloma and novel precision therapeutics like KTX-1001 to address the challenges seen in high-risk patients with translocation t(4;14)."
  • Title: Trial in Progress: A Phase 1 Study of KTX-1001, an Oral, First-in-Class, Selective MMSET Inhibitor in Patients with Relapsed and Refractory Multiple Myeloma

The Multiple Myeloma Research Foundation Announces $21M Grant Program to Support Multicenter Translational Research Networks

Retrieved on: 
Thursday, November 2, 2023
Research, General Health, Philanthropy, Oncology, Genetics, Fund Raising, Foundation, Science, Biotechnology, Other Philanthropy, Other Science, Health, Multiple myeloma, Attention, Multiple Myeloma Research Foundation, MMRF, Doctor of Philosophy, Patient, MAC, HR, Pharmaceutical industry

The Multiple Myeloma Research Foundation (MMRF) announced today the recipients of three $7 million MMRF Myeloma Accelerator Challenge (MAC) Program Grants totaling $21 million.

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) announced today the recipients of three $7 million MMRF Myeloma Accelerator Challenge (MAC) Program Grants totaling $21 million.
  • “These MAC Grants are a critical new part of this investment, and we are excited that the programs selected will bring together multiple centers to work in highly collaborative networks.
  • The first is optimizing first-line therapy for high-risk newly diagnosed multiple myeloma because high-risk patients often relapse early and show inferior survival compared to standard-risk patients.
  • The next is improving identification of high-risk smoldering multiple myeloma (HR SMM); smoldering multiple myeloma is an early, asymptomatic stage that can progress to active multiple myeloma.

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

Retrieved on: 
Thursday, November 2, 2023
Multiple myeloma, CAR, Icahn Genomics Institute, Black, Associate, Washington University in St. Louis, Therapy, CRISPR, Genetics, Bone marrow, Icahn School of Medicine at Mount Sinai, Early Prostate Cancer (clinical programme), Translational research, Doctor of Philosophy, Multiple Myeloma Research Foundation, Research, MAC, Stanford University Medical Center, Mount Sinai Health System, University of California, San Francisco, Genomics, Growth, Disease, MMRF, Immunotherapy, University, Gene, Hackensack University Medical Center, San Francisco, Cancer, Patient, Marc, Pharmaceutical industry, Vaccine, MD

NEW YORK, Nov. 2, 2023 /PRNewswire-PRWeb/ -- The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.

Key Points: 
  • Multiple myeloma is a blood cancer that develops in the bone marrow and can spread throughout the body.
  • In 2023, more than 35,000 Americans are projected to be diagnosed with multiple myeloma and approximately 12,000 will lose their lives.
  • Researchers hope to uncover the full landscape of genomic, proteomic and immune differences between high- and standard-risk multiple myeloma patients.
  • "The three exciting programs we selected each have potential to answer fundamental questions about multiple myeloma and help advance rational treatments for this cancer."

PatientPoint Expands Best-in-Industry Client Strategy, Analytics and Sales Teams

Retrieved on: 
Wednesday, October 25, 2023
Linda, Research, Health, CPG, Physician, Multiple myeloma, Organization, Merck, Multiple Myeloma Research Foundation, Sarli, HCP, DTP, Growth, Enablement, WebMD, Marketing, Genentech, Strategy, DTC, Patient, IQVIA, Wolters Kluwer, Pharmaceutical industry, Indegene

CINCINNATI, Oct. 25, 2023 /PRNewswire/ -- PatientPoint® today announced exciting growth within its client strategy, analytics and sales organizations, further strengthening its best-in-industry team dedicated to amplifying PatientPoint's reach and impact for life sciences and health and wellness brands.

Key Points: 
  • At PatientPoint, Sarli is focused on identifying emerging industry trends, strengthening client engagement and developing case studies to help advance the point-of-care channel.
  • Melanie Spurrier , Vice President, Research and Analytics: Melanie Spurrier brings 20 years of data and analytics and market research expertise to PatientPoint.
  • PatientPoint also continues to expand its Client Sales and Solutions team, recently welcoming these experienced pharmaceutical, health and wellness and media industry sales leaders:
    David Loux , Vice President, Client Solutions: David Loux joins PatientPoint with 15 years of pharmaceutical and healthcare industry sales experience from sales leadership roles at organizations including Indegene, WebMD, Healthcasts and P\S\L Group.
  • "The unrivaled impact PatientPoint delivers to patients, physicians and our client partners starts with our people—and our world-class team is the reason PatientPoint remains the 35-year point-of-care leader," said PatientPoint Chief Client Officer Linda Ruschau.

The Multiple Myeloma Research Foundation (MMRF) Names Stephanie Oestreich, Ph.D., MPA, as Managing Director of the Myeloma Investment Fund (MIF)

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, Health, Other Health, Pharmaceutical, Other Philanthropy, Philanthropy, Oncology, Other Science, Research, General Health, Fund Raising, Health Technology, Foundation, Science, RA, John F. Kennedy High School, Faculty, Business, Drug development, ARCH Venture Partners, Multiple myeloma, Multiple Myeloma Research Foundation, Harvard University, Novartis, American Business Council Nigeria, Arm, Galecto Biotech, Therapy, W20, MMRF, MIT, G20, MPA, Growth, CART, Evotec, Business development, Commercial, Patient, Management, Bruker

The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF).

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF).
  • In this role, Dr. Oestreich will lead the overall execution of the MIF’s investment strategy and serve as a member of the MMRF executive leadership team.
  • “We are thrilled to have Dr. Oestreich join our team as Managing Director of the MIF,” said Michael Andreini, President and CEO, the MMRF.
  • “The MIF invests in the most promising companies that are developing innovative clinical assets and technologies that could be transformative for myeloma patients.

MMRF Research Programs Expand Understanding of the Biology of Multiple Myeloma and Patient-Reported Outcomes in New Data Featured at the 20th IMS Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023
Biotechnology, Health, Philanthropy, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Foundation, Science, Abstract, Patient-reported outcome, Multiple myeloma, PRO, Multiple Myeloma Research Foundation, Publication, Data, Patient, IMS, Biology, Disease, MMRF, Pharmaceutical industry

The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠datasets will be featured in an oral abstract and poster presentations at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece, September 27-30, 2023.

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) today announced that findings from three studies based on analyses of its CoMMpass℠ and CureCloud℠datasets will be featured in an oral abstract and poster presentations at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece, September 27-30, 2023.
  • Topics include:
    A real-world longitudinal investigation of patient treatments and outcomes, including Patient Reported Outcome (PRO) surveys from the MMRF CureCloud Research Initiative
    Additionally, data from the CoMMpass Study are cited in 24 posters and four education sessions, demonstrating its enduring value in driving new advancements across multiple myeloma research.
  • To develop a more comprehensive picture of myeloma disease biology, the MMRF is expanding the CoMMpass dataset with immune data from its Immune Atlas research program.
  • The MMRF makes the datasets from CoMMpass, Immune Atlas, and CureCloud available to researchers, facilitating the development of optimal treatments for all myeloma patients.

Moving Mountains for Multiple Myeloma® Program to Trek Through Alaska, July 23-29

Retrieved on: 
Thursday, July 20, 2023
Fund Raising, Foundation, Philanthropy, GSK, Multiple Myeloma Research Foundation, Friends, Multiple myeloma, Bone marrow, Research, MGUS, Patient, Moving Mountains, Nursing, B cell, Diagnosis, Caregiver, Disease, MMRF, Pharmaceutical industry

The MM4MM Alaska trek is a Multiple Myeloma Research Foundation (MMRF) initiative sponsored by GSK.

Key Points: 
  • The MM4MM Alaska trek is a Multiple Myeloma Research Foundation (MMRF) initiative sponsored by GSK.
  • Since MM4MM began with its first trek in 2016, the program has raised over $3 million for multiple myeloma research.
  • The upcoming Alaska trek will include an extraordinary group of multiple myeloma patients, caregivers, friends and family members, nurses, and team members from the organizing partners.
  • More than 50 years ago, her father passed away from multiple myeloma, and just two years ago, her husband, Ed, was diagnosed with smoldering multiple myeloma.

Akamis Bio Strengthens Leadership Team with Key Executive Appointments

Retrieved on: 
Thursday, July 6, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Yale University, Mace Head Atmospheric Research Station, MIT Sloan School of Management, Business development, Novartis Institute for Tropical Diseases, Research strategies of election campaign communication research, Bluebird bio, Therapy, Biochemistry, Senior, University, Doctor of Philosophy, Bio, Feinberg School of Medicine, University of Hamburg, Business, Bayer, DRS, MBA, Biomedical Research, CMO, Genentech, MIT, Associate, Teaching hospital, PBMC, Harvard Medical School, Research and development, Multiple Myeloma Research Foundation, Takeda Oncology, University of Cologne, Patient, CBO, CD40, Hematology, Swarthmore College, Northwestern University, SQZ, Multiple myeloma, Pharmaceutical industry, Management, Research

as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.

Key Points: 
  • as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.
  • “As CMO, Oliver’s decades of experience in oncology drug development will be critical as we advance our lead program, NG-350A, toward clinical proof-of-concept studies.
  • Dr. Kosa has also held leadership positions at XOMA, Bayer Healthcare, and Connecticut Innovations.
  • She joined Akamis Bio from the Parker Institute for Cancer Immunotherapy in San Francisco where she was Senior Director of Research and Development.

Results of Study on COVID-19 Vaccine Response in Hematopoietic Cell Transplant Patients Published in eClinicalMedicine

Retrieved on: 
Wednesday, May 24, 2023
National Marrow Donor Program, Senior, Survival, National Heart, Lung, and Blood Institute, Bangladesh Technical Education Board, Medical College of Wisconsin, Patient, Risk, Transplant, Data, Leukemia, Database, MCW, Center for International Blood and Marrow Transplant Research, Vaccination, Research, MS, COVID-19, Novartis, Leukemia & Lymphoma Society, III, NIH, Safety, Vaccine, Observational study, Medical college, HCT, Messenger, National Cancer Institute, NMDP, Control, EMMS International, Hematopoietic stem cell transplantation, Multiple myeloma, Blood, SARS-CoV-2, Fred Hutchinson Cancer Research Center, BMT, Lung, Multiple Myeloma Research Foundation, Labcorp, Pharmaceutical industry, MD, Match

“Nonetheless, vaccine responses remained lower than observed in non-immunocompromised patients, underscoring the need for other prevention and treatment strategies.”

Key Points: 
  • “Nonetheless, vaccine responses remained lower than observed in non-immunocompromised patients, underscoring the need for other prevention and treatment strategies.”
    “Vaccination continues to be important following hematopoietic stem cell transplantation (HCT) due to the higher risk of severe COVID-19 infection in these vulnerable patients.
  • “Study results confirm recommendations from the Centers for Disease Prevention and Control for initiating SARS-CoV-2 vaccination early after allogeneic HCT.
  • The results show similar effectiveness in those vaccinated less than four months versus at or after four months post-treatment.
  • The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) conducts rigorous multi-institutional clinical trials of high scientific merit, focused on improving survival for patients undergoing hematopoietic cell transplantation and/or receiving cellular therapies.

Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma

Retrieved on: 
Tuesday, May 16, 2023
Research, Philanthropy, Biotechnology, General Health, Pharmaceutical, Health, Foundation, Science, Oncology, Other Science, Multiple Myeloma Research Foundation, Partnership, Multiple myeloma, PVR, Patient, Investment, Escape Room, Therapy, MMRF, Pharmaceutical industry, Nectin

Nectin Therapeutics , a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF) , the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088, Nectin’s first-in-class lead immunotherapy drug candidate, for the treatment of multiple myeloma.

Key Points: 
  • Nectin Therapeutics , a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF) , the Multiple Myeloma Research Foundation's (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088, Nectin’s first-in-class lead immunotherapy drug candidate, for the treatment of multiple myeloma.
  • "We look forward to our partnership with Nectin Therapeutics to evaluate NTX1088 as a potential therapy for multiple myeloma,” said Michael Andreini, President and Chief Executive Officer of the Multiple Myeloma Research Foundation.
  • “The MIF is committed to identifying and accelerating the most innovative treatment approaches for myeloma patients.
  • We are pleased to support this first-in-class antibody targeting PVR based on the potential to overcome immune evasion and enhance the immune system’s response against myeloma.”
    “We are delighted to join forces with the Myeloma Investment Fund, allowing us to collaborate and explore the potential of our lead candidate, NTX1088, in the treatment of multiple myeloma," said Fabian Tenenbaum, Chief Executive Officer of Nectin.